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Background: The project aim was to review current cost-
effectiveness research for each functional gastrointestinal disor-
der, as deﬁned by the Rome III classiﬁcation system.
Methods: Biomedical databases were searched for articles with the
functional gastrointestinal disorders and their pseudonyms
included in the title, abstract, or medical subject headings, plus the
terms beneﬁt, cost, effectiveness, outcomes, test, utility, or utili-
zation in any search ﬁeld.
Results: Highly prevalent conditions such as dyspepsia and irrita-
ble bowel syndrome have advanced cost-effectiveness analyses
including cost–utility studies that have helped support current
management guidelines. The rarer functional gastrointestinal dis-
orders have few or no published cost-effectiveness analyses, but
the Rome III classiﬁcation system provides a framework for iden-
tifying the speciﬁc cost data or outcomes measures available or
needed for future research.
Conclusions: The Rome process has provided a useful system for
deﬁning the functional gastrointestinal disorders and identifying
speciﬁc clinical questions to be examined using cost-effectiveness
analysis techniques.
 2013 The Author. Published by Elsevier Ltd.
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The functional gastrointestinal disorders are a collection of conditions affecting every part of the
gastrointestinal that share most of the following features: (1) the underlying pathophysiologic
mechanisms are largely unknown; (2) they do not have an anatomic or traumatic defect that could
cause the dysfunction; (3) they are not related to a metabolic abnormality such as hypothyroidism; (4)
they cause symptoms that are often vague and difﬁcult to localize; (5) they are (dys)functional in that
the normal neuromuscular function of the affected part of gastrointestinal tract is impaired and/or
causes discomfort; (6) psychosocial factors may affect the susceptibility to gut dysfunction and the
ability to cope with symptoms [1]. Historically, the vague or unusual nature of the signs and symptoms
often caused the patient or physician to dismiss them as being caused by stress or undiagnosed psy-
chiatric disorders. However, recent efforts to categorize and systematically study the functional
gastrointestinal disorders have substantially changed the perspective about these syndromes, some of
which are among the most common problems managed by primary care physicians [2].
The ‘Rome criteria’ have come about as part of an international effort to improve the diagnosis and
treatment of functional gastrointestinal disorders [1,3]. Whatwas initially an effort to bring organization
to diagnostic criteria for irritable bowel syndrome evolved into a system to categorize all of the functional
gastrointestinal disorders and deﬁne symptom-based diagnostic criteria for each category [1]. The Rome
process has used a ‘Delphi’ method to rigorously organize the committees of international experts to
develop consensus in each disorder. The adult disorders are organized into six major domains: esoph-
ageal, gastroduodenal, bowel, functional abdominal pain syndrome, biliary, and anorectal (Table 1).
Within each domain are several disorders which are characterized primarily by their symptoms and
locations. This system allows for the development of speciﬁc criteria for each disorder that can be more
reliably reproduced frompopulation to population. Even though several functional disordersmight share
similar symptoms, the cluster of symptoms used to describe a speciﬁc disorder provides a framework for
organizing the other clinical information needed to establish a diagnosis. This can be helpful both in the
approach to managing an individual patient and in organizing similar patients for clinical research.
The purpose of this review is to examine the current state of the science of cost-effectiveness ana-
lyses for each adult Rome III deﬁned functional gastrointestinal disorder. These disorders run the gamut
from the very common, such as functional dyspepsia, to the very rare, such as rumination syndrome.
Correspondingly, some disorders have a wealth of articles relevant to cost-effectiveness, cost–beneﬁts,
or cost–utilities, while rarer ones have no published research that speciﬁcally address these issues. For
the common syndromes, we have selected those articles that are current and have themost relevance to
themanagement of patients in clinical practice. For rare syndromes and those lacking cost-effectiveness
analyses, we have identiﬁed articles that may not have speciﬁcally addressed cost effectiveness, but do
provide information relevant to capturing the fundamental aspects of cost analyses, such as utilization
perspective (payer, provider, patient, or societal), outcomes (diagnostic accuracy, symptom change,
quality of life), or utility measures such as quality-adjusted life years (QALYs).Functional esophageal disorders
Functional heartburn
Functional heartburn is variably deﬁned but usually described as persistent heartburn symptoms
with normal ﬁndings on endoscopy (e.g., no grossly visible signs of oesophagitis) and normal routine
24-h esophageal pH monitoring [4,5]. It is also referred to as functional pyrosis, and due to advances in
combined pH and reﬂuxmonitoring technology and growing experiencewith themanagement of non-
erosive esophageal disease in tertiary referral centres, some extend the deﬁnition to exclude thosewho
are symptomatically responsive to high-dose proton pump inhibitors and patients who have evidence
of esophageal reﬂux, motility alterations, or structural morphological abnormalities [6]. The patho-
physiology of functional heartburn is not well understood but thought to be related to abnormalities
in the peripheral and central nervous system that result in hypersensitivity to relatively normal
stimuli [4,5].
Table 1
The Rome III adult functional gastrointestinal disorders.a
A. Functional esophageal disorders
1. Functional heartburn
2. Functional chest pain
3. Functional dysphagia
4. Globus
B. Functional gastroduodenal disorders
1. Functional dyspepsia
a. Postprandial distress syndrome
b. Epigastric pain syndrome
2. Belching disorders
a. Aerophagia
b. Unspeciﬁed excessive belching
3. Nausea and vomiting disorders
a. Chronic idiopathic nausea
b. Functional vomiting
c. Cyclic vomiting syndrome
d. Rumination syndrome in adults
C. Functional bowel disorders
1. Irritable bowel syndrome
2. Functional abdominal bloating
3. Functional constipation
4. Functional diarrhoea
5. Unspeciﬁed functional bowel disorder
D. Functional abdominal pain syndrome
E. Functional gallbladder and sphincter of Oddi disorders
1. Functional gallbladder disorder
2. Functional biliary sphincter of Oddi disorder
3. Functional pancreatic sphincter of Oddi disorder
F. Functional anorectal disorders
1. Functional fecal incontinence
2. Functional anorectal pain
a. Chronic proctagia
i. Levator ani syndrome
ii. Unspeciﬁed functional anorectal pain
b. Proctalgia fugax
3. Functional defecation disorders
a. Dyssynergic defecation
b. Adequate defecatory propulsion
a Derived from the Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders (www.romecriteria.org/criteria/) and
Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130: 1377–1390.
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functional heartburn to date. However, advances in impedance-pH monitoring combined with
symptom-association assessment is proven to have substantially improved diagnostic utility and efﬁ-
ciency in the evaluation of possible functional heartburn, especially as compared to pHmonitoring alone
[7]. Empirical treatment with pain modulators such as tricyclic antidepressants or selective serotonin-
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management can help avoid unnecessary invasive tests and therapeutic procedures [5,8].
Functional chest pain of presumed esophageal origin
Functional chest pain is the Rome III terminology for recurrent angina-like retrosternal chest pain
with normal coronary anatomy and no detectable gastroenterological or respiratory causes, but also
goes by a variety of pseudonyms including non-speciﬁc chest pain, non-cardiac chest pain, atypical
chest pain, syndrome X, and chest pain with normal coronary anatomy. One population-based
Australian survey found that functional chest pain was noted by approximately 5% of all persons
reporting a functional gastrointestinal disorder [9]. Although there are very few published in-
vestigations into the speciﬁc causes of this disorder, there is objective evidence that indicates that some
patients have neuronal dysfunction that results in visceral hyperalgesia [10,11]. However, increased
prevalences of stress, anxiety, and psychiatric disorders have been reported in persons with functional
chest pain, and treatment with antidepressants has been proven effective in randomized clinical trials
[12]. Most expert review articles suggest an empiric approach to management beginning with empiric
treatment for GERD [5,11].
A study by Borzecki et al examined the cost-effectiveness of empiric therapy of non-cardiac chest
pain as GERD using decision analysis techniques [13]. Patients were assumed to already have a normal
coronary angiogram. Patients empirically treated with omeprazole or ranitidine had cost estimated at
$849 per patient versus $2187 for those who underwent diagnostic assessment for an esophageal
disorder, a cost difference that is most likely even greater now that these medications are less
expensive. Another decision analysis study of similar design that began with empiric therapy but
included diagnostic evaluation for those who failed treatment found substantial cost savings as
opposed to initiating a diagnostic work up for all cases, with improved diagnostic accuracy and greater
reduction in symptoms at 12 months [14].
Functional dysphagia
Functional dysphagia is the presence of dysphagia symptoms in the absence of structural disorders,
motility disturbances, or gastro-esophageal reﬂux disease [5]. Dysphagia is a very common symptom,
and the manifestation of a wide range of disorders, so one must sort through a complex algorithm of
diagnostic possibilities before arriving at functional dysphagia [5,15]. In a case-series review of patients
referred for evaluation of dysphagia at an otolaryngology-based tertiary referral centre, only 13% could
not be found to have speciﬁc aetiology for the symptom after a complete diagnostic evaluation [16].
The development of high-resolution manometry has improved the detection and diagnosis of
esophageal motility disorders and reclassiﬁes many patients who would have been diagnosed as
functional or idiopathic dysphagia to speciﬁc and treatable neuromuscular conditions [17]. We did not
locate any published articles that addressed the cost-effectiveness of functional dysphagia diagnosis or
management.
Globus
Globus (Latin for globe or ball) is the sensation of a lump in the throat, typically felt at the level of
the larynx, and often triggered by an intense emotional event. The ‘globus response’ is a common
experience reported by approximately half of apparently healthy individuals, and was described by the
ancient Greek physician Hippocrates [18]. Men and women are equally affected, but women thought
more likely to seek medical evaluation and treatment [5,19].
Globus is regarded as a benign symptom, so the initial management is focused on excluding rare but
potentially serious causes such as laryngopharyngeal tumours and thyroid disease [19]. The few clinical
articles that discuss costs as a consideration in globus evaluation are from the perspective of the
relative efﬁcacy of various diagnostic tests in ruling out laryngeal cancer. In an analysis of the clinical
use and economics of laryngoscopy for nasolaryngeal complaints including globus (32% of the 276
retrospective patient cohort) in a family practice clinic, Wilkins et al concluded that this was a safe and
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unnecessary referral to specialists and additional procedures [20]. A retrospective review of 1145 pa-
tients with globus pharyngeus who had a barium swallow did not ﬁnd any with a pharyngeal or
esophageal cancer, and thus the authors concluded that this test was not cost-effective as part of the
routine evaluation for globus [21]. The causal association between gastro-esophageal reﬂux disease
(GERD) and globus is controversial, but a trial of empiric GERD treatment is recommended as a
reasonable and inexpensive ﬁrst step after initial evaluation [19].
Functional gastroduodenal disorders
Functional dyspepsia
Dyspepsia is another very common gastrointestinal symptom, and although the incidence of
dyspepsia varies by age, sex, ethnicity or race, and geographic region, most persons will experience
dyspepsia at least once in their lifetime [22]. Functional dyspepsia is deﬁned as dyspepsia that is not
associated with structural defects such as gastro-esophageal reﬂux, gastric or peptic ulcers, or choleli-
thiasis, and not due tometabolic or neurologic conditions such as pancreatitis or gastric dysmotility [23].
In contrast to functional gastrointestinal disorders such as functional dysphagia where the diagnosis is
not made until all other speciﬁc causes are excluded, it is assumed that approximately two-thirds of
patients with dyspepsia will not have a speciﬁc cause readily identiﬁable, so diagnostic algorithms for
dyspepsia eventually label most cases as ‘functional dyspepsia.’ [24] A high proportion of functional
dyspepsia is attributable toHelicobacter pylori gastritis, somost expert consensus guidelines recommend
a ‘test and treat’ approach to screen for H. pylori [23,25]. Persons with ‘alarm features’ (weight loss,
progressive dysphagia, recurrent vomiting, gastrointestinal bleeding, or family history of gastric cancer)
that might suggest a malignancy should not have their dysphagia managed empirically [24,25].
In contrast to most other functional gastrointestinal disorders, there are many articles examining
cost-effectiveness issues in functional dyspepsia, including some that focus on very small facets of
diagnosis or treatment. Indirect medical costs (those that are incurred by the patient or society) were
examined in a survey of 355 patients who met the Rome III criteria for functional dyspepsia [26]. The
mean patient expenditure of over-the-counter medications was $246 (range $0–$12,000), $290 for co-
payments (range $0–$9000), $110 for alternative treatments (range $0–3741), and a mean of 1.4 h lost
work time in the week prior to the survey. In a case–control analysis of direct medical costs for 6989
dyspepsia patients, marginal excess costs attributable to the initial evaluation and management of
dyspepsia were a mean $483 greater than controls, but dyspepsia patients were also found to have
higher direct medical costs overall well before and after the initial diagnosis of dyspepsia was made
[22]. The cost-effectiveness of six different H. pylori non-invasive diagnostic tests was examined using
Markov modelling within the context of applying the recommended ‘test and treat’ approach for
dyspepsia management in typical practice pattern in the United States [27]. The cost per symptom-free
year was $122 USD for empiric proton pump inhibitor therapy, and the costs per symptom-free year for
the various non-invasive H. pylori tests ranged from $122.13 to $129.04, with wide overlap in conﬁ-
dence intervals. This same analysis examined a cost per correct diagnosis approach, wherein onewould
continue to pursue the diagnosis independent of whether the patient experienced symptomatic relief.
The cost per correct diagnosis ranged from $2768 for the stool antigen test to $4062 for IgG/IgA binary
serology, which illustrates how the relative cost–beneﬁt of various diagnostic testing strategies should
include consideration of the subsequent beneﬁts to the patient, and not just the diagnostic precision of
the test.
In the CADET-Hp study, a randomized clinical trial that enrolled 294 patients from 36 family
practices in Canada, dyspepsia patients who had a positive 13C-urea breath test were given either
eradication therapy or placebo and followed for one year [28]. The proportion of patients who
considered treatment to be a success was 50% in the treatment group versus 36% in the placebo
(P ¼ 0.02), and treated patients also had greater improvement in three of ﬁve quality of life domains.
Treatment reduced mean societal costs by $53 and mean direct medical costs by $45, indicating that H.
pylori eradication therapy was the cost-dominant alternative for most individuals who have a positive
13C-urea breath test.
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effective as compared to empiric acid treatment alone without any H. pylori testing [29]. Eighty gen-
eral practices in the United Kingdom recruited adults aged 18–65 with dyspepsia per the Rome I
criteria, and randomized 343 to the ‘test and treat’ protocol with 13C urea breath testing for H. pylori
and clarithromycin/metronidazole/omeprazole for those testing positive or just omeprazole for those
testing negative, and 356 to the empiric group whowere treated with 20 mg omeprazole a day for four
weeks. At 12 months there were no differences between the ‘test and treat’ group and the empiric acid
suppression group in terms of costs, dyspepsia symptom reduction, or quality-adjusted life years,
suggesting that empiric acid suppression is an appropriate strategy. However, as the authors point out
in their discussion, there are other potential beneﬁts of H. pylori eradication that were not accounted
for in this trial, namely the potential reduction in the risk for MALT lymphoma and gastric cancer.
Therefore, the ‘test and treat’ approach is preferable in regions where the prevalence of H. pylori is very
high, but the empiric acid suppression treatment approach is reasonable in populations where the
prevalence of H. pylori infection is very low.
Now that proton pump inhibitors are available over-the-counter, a relevant question is whether
those who are chronically self-medicating for dyspepsia beneﬁt from testing for and eradication of H.
pylori infection. The HELPUP trial randomized 183 patients who were on long-term proton pump in-
hibitor therapy for dyspepsia and had a positive 13C urea breath test for H. pylori to treatment with
lansoprazole/amoxicillin/clarithromycin or lansoprazole plus placebos [30]. Patients on eradication
therapy had signiﬁcant reduction of dyspepsia symptoms and utilization for GI-related health care
including primary care visits, endoscopies, ultrasound, and prescription ﬁlls. Net cost savings at two
years were a mean of £93 (95% CI: 33–153), making eradication therapy cost-dominant. The prevalence
of H. pylori infection in the screened population was 31%, but a sensitivity analysis determined that
eradication therapy would continue to be signiﬁcantly cost-dominant down to a prevalence of 20%.
The use of ‘alarm features’ criteria to determine which dyspepsia patients have early endoscopic
evaluation creates the possibility of missed esophageal or gastric carcinomas among those deferred to
empirical treatment. A largemulti-national study (the STARS I Study Group) examined the incidence of
malignant and non-malignant abnormalities among persons with new-onset dyspepsia by Rome II
criteria absent alarm features [31]. A total of 2741 patients from 17 countries underwent endoscopy,
and their costs were stratiﬁed by age-deﬁned cohorts to examine cost-effectiveness by variable age
criteria. Only six carcinomas were found (three esophageal, three gastric), with only one of these
occurring in a patient below 50 years of age. If the age threshold was set at age 50 and endoscopy
assumed to cost $500, the average cost per cancer detected would be $82,900 US (95% CI: 35,714–
250,000). If all patients had endoscopy regardless of age, the average cost per cancer detectedwould be
$228,417 US (95% CI: 104,167–625,000). The authors concluded that age 50 was an appropriate cut
point for application of the alarm features criteria.
Postprandial distress syndrome & epigastric pain syndrome
The Rome III criteria introduced these subgroups of functional dyspepsia to help distinguish be-
tween different symptom clusters within dyspepsia that might have different mechanistic, prognostic,
and treatment signiﬁcance [23]. Epigastric pain syndrome is intermittent pain or a burning in the
epigastrium of moderate or greater severity, occurring at least once per week, not relieved by defe-
cation or passing gas, and not fulﬁlling criteria for gallbladder or sphincter of Oddi disorders. Post-
prandial distress syndrome is postprandial fullness after ordinary sized meals and early satiation
preventing ﬁnishing a regular meal at least several times per week. However, since these are relatively
new criteria, there are few studies that indicate how useful these symptom-based subgroups will be. In
a study of very thoroughly assessed functional dyspepsia patients in Japan, the epigastric pain syn-
drome and postprandial distress syndrome criteria did not help discern the underlying pathophysio-
logic abnormalities [32].
Belching disorders: aerophagia & unspeciﬁed excessive belching
Aerophagia is a rare behavioural disorder that results in excessive belching. Air is normally swal-
lowed along with food or ﬂuids while eating and it collects in the upper stomach when the patient is
upright. Reﬂex mechanisms eventually cause the lower esophageal sphincter to relax so the gastric air
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frequency in persons with and without aerophagia. Esophageal impedance studies conﬁrm that the
belching among persons with aerophagia comes from swallowed air that usually only reaches the
upper third of the oesophagus before it is immediately expelled, which are described as supragastric
belches [33]. The key distinction between aerophagia and unspeciﬁed excessive belching is that in the
latter there is no evidence of excessive air swallowing, which can be demonstrated by esophageal
impedance monitoring [23].
Available data suggests that the impact of aerophagia on health status is substantial. In a retro-
spective analysis of patients seen at the Mayo Clinic in Rochester, Minnesota, aerophagia was also
associated with increased abdominal pain (19%), bloating (27%), and abdominal distention (19%) [34].
Health related quality of life, as measured by subscales in the generic health status instrument SF-36,
may be substantially negatively affected among persons with aerophagia [35].
Nausea and vomiting disorders
Four distinct syndromes are included under the Rome III subcategory of nausea and vomiting
disorders: chronic idiopathic nausea, functional vomiting, cyclic vomiting syndrome, and rumination
syndrome [23,36]. These have replaced the term ‘psychogenic vomiting’, which previously was used to
describe all unexplained vomiting based on the unfounded belief that most of these cases had an
underlying undiagnosed psychiatric illness. Each of these syndromes is rare, and as such there are scant
data about costs, useful diagnostic tools, or effective treatment.
Chronic idiopathic nausea
This syndrome is characterized by persistent nausea occurring several times per week without
vomiting [23,36]. The main distinction between chronic idiopathic nausea and non-ulcer dyspepsia is
the lack of epigastric pain or symptoms related to eating. H. pylori in a case-series review of 248 pa-
tients referred to a tertiary referral centre for a chief complaint of chronic nausea or vomiting, chronic
vestibular dysfunction was proven to be a commonly missed cause (26% of cases), and only 31%
remained ‘idiopathic’ after a complete evaluation [37]. There are no methodologically rigorous studies
on treatment, but antidotal reports suggest a range of possible approaches [38].
In a large registry based study, chronic idiopathic nausea patients had clinical and demographic
characteristics that were almost indistinguishable from persons with gastroparesis [39]. The gastric
emptying timeasmeasuredby technetiumscintigraphywas the onlymajordifferencebetween these two
groups, although the gastric emptying time does not correlate with the severity of symptoms in either.
Functional vomiting & cyclic vomiting syndrome
Functional vomiting is distinct from cyclic vomiting in that it happens at least once aweek and does
not have any long symptom-free periods. Both syndromes require the absence of any laboratory or
radiographic abnormalities that might explain these symptoms [23]. It has recently been recognized
that there are a few other clinical characteristics that help differentiate these syndromes [40]. In a
systematic comparison of functional vomiting and cyclic vomiting patients seen at the Mayo Clinic in
Rochester, Minnesota, the cyclic vomiting syndrome patients were more commonly males (60%),
younger (mean age 30), and cannabis users (37%). The associationwith cannabis use has been noted by
others, and it appears that some patients are self-medicating with cannabis in the belief that it helps to
control their symptoms, when in fact cannabis can make cyclic vomiting acutely worse.
The cyclic vomiting syndromewas initially recognized in children, but is now known to occur at any
age [41]. This syndrome is characterized by periods of severe nauseawith vomiting that typically last for
about six days (range: 1–21 days), then completely resolve for months before occurring again. Afﬂicted
individuals develop a predictable pattern of symptoms in both onset and duration, thus earning the
term cyclical, but unfortunately this pattern may not be recognized until it has run for years.
Rumination syndrome
Rumination is the regurgitation without forceful vomiting of undigested food from the stomach to
themouth, where it may be swallowed again or spit out [42]. There is no nausea or retching, and it may
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treated with proton pump inhibitors, which may reduce pain from the acid burning of the oesophagus
but paradoxically worsen the behaviour by removing a major deterrent. Rumination can be diagnosed
by Ambulatory pH/impedance monitoring can be helpful in establishing the diagnosis of rumination
and to help distinguish it from esophageal regurgitation and belching [43].
Functional bowel disorders
Irritable bowel syndrome
Irritable bowel syndrome (IBS) is a functional disorder characterized by recurrent abdominal pain or
discomfort associated with changes in the form or frequency of stool, and generally improved after
defecation [44]. It is very common, with an estimated prevalence among adults approximately 10%
based on validated symptoms questionnaires, and most surveys ﬁnd that IBS is more common among
women [45,46]. There are three main sub-types: diarrhoea-predominant (IBS-D), constipation-
predominant (IBS-C), or mixed diarrhoea-constipation (IBS-M) [44]. Most persons diagnosed with
IBS will be symptomatic for years [47], but fortunately IBS does not appear to be related to risk for
developing any other serious disease, and is not associated with increased mortality [46].
In the absence of ‘alarm symptoms’ (age of onset >50, nocturnal symptoms, weight loss, rectal
bleeding, family history of colon cancer, or recent antibiotic use) the Rome III criteria have a 98%
positive predictive value for IBS [48], and thus guidelines encourage diagnosis based on history and
physical alone [44,46,49]. Therefore, even though IBS is described as chronic disorder of gastrointes-
tinal function in the absence of detectable organic disease, it is not a diagnosis of exclusion. This
contradiction is a point of confusion for many primary care providers and gastroenterologists. In a
survey that included IBS mostly academic experts, practicing gastroenterologists, and primary care
providers, only 8% of the experts agreed that IBS is a diagnosis of exclusion, as compared to 72% of all
others [50]. This discrepancy is reﬂected in substantially higher testing among primary care providers
(mean 2.0 tests per case among IBS experts versus 4.1 among all other providers; P < 0.01), which
translates intomuch higher costs for tests that have very low probability of being useful (mean US $297
per case among IBS experts versus $658 among all other providers; P < 0.01). This analysis highlights
an opportunity where improved implementation of evidence-based guidelines could have large cost–
beneﬁts.
One screening test that most IBS experts support is serology for celiac disease [50]. Celiac disease,
also known as gluten-sensitive enteropathy, may present with symptoms identical to any of the IBS
sub-types, and studies based on populations of suspected IBS have found prevalences of celiac disease
ranging from 0% to 11% [51]. Because celiac disease requires much different treatment than IBS (spe-
ciﬁcally – avoidance of gluten) with the potential to substantially reduce chronic symptoms and
improve quality of life, screening for celiac disease among IBS would logically seem to be cost-effective,
and a series of analyses suggest that is the case. An analysis based on screening all patients with
suspected IBS with either a test for only the tissue transglutaminase antibody (US $68 per test) or an
antibody panel (US $128 per test) found a mean cost per case detected of $4600 with the tissue
transglutaminase test and $8800 for the panel, with a highly favourable cost per QALY of $7400,
assuming a celiac disease prevalence of 3% [52]. The incremental cost per QALY for using the more
expensive panel test ($287,000) was not favourable. Patients with IBS-D symptoms are thought to have
an even higher prevalence of celiac disease, so another modelling analysis restricted the study pop-
ulation to IBS-D only and performed sensitivity analyses including an assessment assuming variable
prevalences of celiac disease in the population [51]. In this analysis, which assumed a base-case celiac
disease prevalence of 3.4% and celiac testing cost of US $80 per person, the cost per case detected was
$11,000. However, in sensitivity analyses celiac screening had a favourable cost-effectiveness proﬁle
with celiac disease prevalence ranging from 1% to 8%, and celiac disease screening was cost-dominant
(i.e., the beneﬁts more than pay for the testing) at prevalences greater than 8%. A more recent analysis
of celiac disease screening in patients with IBS-D or IBS-M, assuming a conservative estimate of 3%
prevalence, estimated a cost of V6200 per QALY, which is a very favourable cost/beneﬁt proﬁle
especially considering that it only considers direct medical cost [53].
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90% of symptomatic individuals meeting Rome IBS criteria do not seek medical attention [46]. To
identify the factors associated with increased healthcare cost and utilization among persons with IBS,
Williams et al conducted a survey of patients enrolled in one regional managed care system and linked
each individual’s responses to their cost data captured in an administrative database [54]. Among the
337 respondents (98 men, 239 women) there were no differences in healthcare utilization overall by
sex, but the reasons that men and women sought treatment for their IBS did vary substantially [54].
Women were more likely to seek help if they were age 55 years or older, afraid their symptoms were
signs of serious illness, and had pelvic pain or decreased bowel movements. Men were more likely to
seek help if they had abdominal cramping or were disabled. Pain severity and mental health status
were not factors associated with seeking care among either sex.
Functional bloating
The diagnosis of functional bloating is used for symptoms of bloating or visible abdominal
distention at least three days a month, but insufﬁcient symptoms to meet the criteria for IBS or
functional dyspepsia [44,55]. Bloating and distention are common symptoms found in other functional
gastrointestinal disorders, and population-based surveys have found that most patients with these
symptoms can be included in one of the other syndromes [56,57]. Nevertheless, functional bloating is
very common and reported by 7%–10% of the participants of these surveys. Many studies have
examined treatment of bloating and distension as a part of the management of other gastrointestinal
syndromes, but none have focused speciﬁcally on patients with functional bloating [57].
Functional constipation
Functional constipation is also known as chronic idiopathic constipation, and may be deﬁned as
constipation that does not have an anatomical or physiological cause and occurs at least two days a
week for at least three months, but does not have sufﬁcient criteria for IBS [44]. The main distinction
between functional constipation and IBS per the Rome III criteria is that the primary criteria for IBS
emphasize the problem of abdominal pain. In fact, a recent study suggests that physiologically the only
difference between functional constipation and IBS is increased sensitivity to pain stimuli in the latter,
as indicated by response to serotonin levels [58]. Functional constipation is also relatively common,
with a prevalence ranging from 7.4% to 30%, varying by region, sex, and age [57,59].
Laxatives and other treatments for functional constipation tend to be inexpensive, so it is not
difﬁcult for a treatment with a relatively modest improvement in efﬁcacy to demonstrate cost-
effectiveness. For example, in a cost effectiveness model based on clinical trial data, polyethylene
glycol improved treatment efﬁcacy by only 42% compared to 31% for lactulose, but only increased
treatment costs by UK £13 over three months, resulting in a highly favourable cost per QALY of UK
£4333 [60]. Chronic constipation has a measurable impact on symptoms, health status, and quality of
life, so it is feasible to describe treatment cost–beneﬁts in multiple domains [60,61]. Functional bowel
disorders including constipation are a popular area for complementary and alternative medicines,
including herbs such as ginger and peppermint oil or message therapy, and a prospective study of
patients with bowel disorders in one medical system found that 35% of the cohort was using these
therapies with costs and outcomes that were very similar to the prescribed treatments [62].
It is important to distinguish functional constipation from the functional defecation disorders
(Section Functional defecation disorders), which have the same symptoms criteria, but the latter are
due to physiologically demonstrated problems with either inadequate propulsive forces or inappro-
priate contraction of the pelvic ﬂoor muscles [1].
Functional diarrhoea
Functional diarrhoea is deﬁned by the Rome III diagnostic criteria as loose or watery stools without
pain occurring in at least 75% of movements [44]. The primary distinction between functional diar-
rhoea and IBS-D is the association with abdominal pain in the latter. Prevalence estimates are difﬁcult
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based analysis of 16,708 individuals in China that used the Rome II criteria, 248 individuals (1.54% of
respondents) had functional diarrhoea, as compared to 277 (1.72%) who had IBS-D [63]. This survey
also demonstrated that functional diarrhoeawas associated with lower health status in ﬁve of eight SF-
36 domains as compared to those without bowel disease, and the clinical characteristics and de-
mographics of functional diarrhoea and IBS-D patients were very similar, but the diarrhoea symptoms
in IBS-D were substantially more severe. A population-based analysis of functional bowel disorders
among 18,180 survey participants in Iran found that functional diarrhoea was the most uncommon
functional bowel disorder (0.2% of the cohort) and the direct and indirect costs attributed to functional
diarrhoea were negligible as compared to the other bowel syndromes [64]. However, since functional
diarrhoea is a diagnosis of exclusion, one could undergo a battery of very expensive and not very useful
diagnostic tests looking for the wide range of causes of diarrhoea, so following a logical algorithmic
approach to diagnosis is the most important cost-effective intervention in this syndrome [65].
Unspeciﬁed functional bowel disorder
This syndrome may be deﬁned as chronic bowel symptoms not attributable to an organic aetiology
that do not ﬁt in any other Rome III category [44]. This vague syndrome is actually among the most
common functional gastrointestinal disorders in some population-based surveys [57,66,67]. It is also
among the most expensive of the functional bowel syndromes in terms of both direct and indirect
costs, although very few studies devote attention to either costs or outcomes in unspeciﬁed functional
bowel disorder [68].
Functional abdominal pain syndrome
The Rome III diagnostic criteria for the functional abdominal pain syndrome require all of the
following: continuous or nearly continuous abdominal pain; no clear relationship with physiologic
events such as eating; some loss of daily function; insufﬁcient symptoms to meet criteria for another
functional gastrointestinal disorder; and absence of ‘malingering’, which is fabricating or exaggerating
the symptoms of physical disorders for secondary gain motives such as ﬁnancial compensation [69].
The last criterion is a nuanced one since patients with this disorder typically complain of symptoms
disproportionate to any objective ﬁndings, and this syndrome is commonly associated with somati-
zation disorder. There are very few epidemiologic data describing the prevalence of functional
abdominal pain syndrome, but it is regarded as being rare as compared to the other functional
gastrointestinal disorders [70]. The syndrome is thought to have a variety of causal mechanisms, but
the current theories suggest neurologic dysfunction, either in peripheral visceral nerves or in central
pain pathways, results in either heightened sensitivity to normal stimuli or defects in central pro-
cessing and attenuation of pain signals [71]. These theories are supported by the fact that medications
that affect neuropathic pain, such as tricyclic antidepressants, selective serotonin-reuptake inhibitors,
and gabapentin can be helpful for some patients. Although there are no studies speciﬁcally examining
cost-effectiveness aspects of chronic functional abdominal pain, it is recommended that in the absence
of alarm symptoms, expensive and invasive diagnostic evaluations be avoided [69].
Chronic functional abdominal pain typically results in considerable limitation in daily functional
capacity, which in turn leads to both high indirect costs and increased health care seeking behaviour
[72]. A multidisciplinary approach including pain specialists and psychologists skilled in chronic pain
and chronic illness is recommended.
Functional gallbladder and sphincter of Oddi disorders
In contrast to the other functional gastrointestinal disorders, most cases of functional gallbladder
and sphincter of Oddi disorders can be attributed to speciﬁc neuromuscular defects: inadequate
gallbladder contraction after stimulus in the former, and inadequate sphincter of Oddi relaxation in the
latter [73]. However, in keeping with the Rome system of using symptom-based criteria to deﬁne
functional gastrointestinal disorders, the Rome III criteria require all of the following basic criteria:
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enough to disrupt daily activities; not explainable by structural abnormalities including cholelithiasis;
and not relieved by bowel movements, postural change, or antacids [73]. This category is divided into
three sub-categories: functional gallbladder disorder, functional biliary sphincter of Oddi disorder, and
functional pancreatic sphincter of Oddi disorder.
Functional gallbladder disorder
The Rome III diagnostic criteria for functional gallbladder disorder require in addition to the basic
criteria noted previously, normal liver and pancreatic enzymes, and an intact gallbladder [73]. A
transabdominal ultrasound is required to exclude gallstones and structural abnormalities of the biliary
system, and upper gastrointestinal endoscopy is usually indicated to exclude abnormalities in the
oesophagus, stomach, and duodenum that might explain epigastric pain, and to collect bile to rule out
microlithiasis. Because functional gallbladder disorder is so closely associated with dysfunction of
gallbladder contractility [74], a gallbladder ejection fraction of <38% as measured by cholecystokinin-
cholescintigraphy has become a diagnostic standard, at least in the United States [75].
Cholecystectomy is the recommended treatment for persons diagnosed with functional gallbladder
disorder [73]. However, there has only been one prospective randomized controlled trial that
compared cholecystectomy to medical management for persons with reduced gallbladder ejection
fraction, and that study was conducted in only one hospital and randomized a total of only 21 patients
[76]. The epidemiology and natural history of gallbladder dyskinesia are unknown, and some have
noted the lack of objective data supporting current diagnosis and treatment recommendations [77–
80]. In a recent study comparing regional differences in hospitalizations and cholecystectomies for
biliary dyskinesia across the United States, the annual admission rate was found to vary from 1.1  0.1/
100,000 in Oregon to 7.4  0.4/100,000 in West Virginia, and the surgery rate varied from 55% (2.4%)
inMaryland to 82.5% (1.9%) in Utah [78]. These regional differences were signiﬁcantly associatedwith
overall hospitalization rates, the number of physicians available in an area, and practice patterns for
treatment of cholelithiasis and cholecystitis, and suggest that socioeconomic factors and local medical
culture may have more inﬂuence on diagnosis and treatment decisions than variations in the natural
progression of functional gallbladder disorder. Cost-effectiveness analyses have not been published for
this syndrome, but the growing rate of diagnosis and surgery for biliary dyskinesia, especially in
children [81], suggest that this is an area where speciﬁc data on both costs and effectiveness could
improve care and reduce costly and unproductive testing and procedures.
Functional biliary sphincter of Oddi disorder
Sphincter of Oddi dysfunction is characterized by abnormalities in sphincter contractility [74]. Most,
but not all, of these cases occur in persons who have had cholecystectomy, and among all who have
cholecystectomy, it occurs in less than 1.5% [82,83], although epidemiologic studies have not been
repeated since laparoscopic techniques have substantially changed this procedure and increased the
number performed. The Rome III deﬁnition for functional biliary disorder requires all of the basic
criteria noted for this section plus normal pancreatic enzymes [73]. The ‘Milwaukee Criteria’ system
further divides this class into types I, II, and III based on the size of the common bile duct and liver
function tests, with Type I having both a dilated common bile duct and abnormal liver blood tests
associated with symptoms on two occasions, Type II having either a dilated common bile duct or
abnormal liver function tests, but not both, and Type III having neither [74]. Gong et al have proposed
adding two additional sphincter of Oddi dysfunction categories, a double-duct-type and a biliary-
pancreatic-reﬂux type, to better categorize these patients who do not ﬁt well into the Milwaukee
system [84].
The evaluation and treatment of sphincter of Oddi dysfunction is a controversial topic. Obstruction
at the sphincter of Oddi may result in increased pressure within the biliary and/or pancreatic duct, and
small randomized clinical trials and observational studies suggested that manometry demonstrating
an increased basal pressure >40 mmHg in the duct is a highly signiﬁcant predictor of successful
treatment with sphincterotomy [85,86]. However, manometry of the ducts must be performed in
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technical and expensive procedure with a high risk of complications including symptomatic pancre-
atitis, so performing ERCP with biliary and pancreatic duct manometry on all cases of sphincter of Oddi
dysfunction is not advised [73]. Furthermore, case-series reports with mean follow-up observation
more than 12 months show that the great majority of patients with Type III sphincter of Oddi
dysfunctionwill have improvement or complete resolution of symptoms without sphincterotomy [87].
However, advocates of manometry point out that the correlation between manometry pressures and
Milwaukee grade is poor, and that in some hands manometry is still a better predictor of response to
sphincterotomy [86,88].
Patients with Type I dysfunction (both dilated common bile duct and elevated liver enzymes) tend
to have a favourable response to ERCP, so expert consensus suggest that Type I patients may proceed to
sphincterotomy without manometry [73,89]. However, in a study of a small cohort of patients with
proven sphincter of Oddi dysfunction who were encouraged to have medical management only for at
least a year, approximately half of those with Type I criteria had symptomatic improvement [90]. This
suggests that conservative medical treatment is a reasonable and less costly alternative for some Type I
patients.
The evaluation and treatment of persons with Type II criteria are still problematic. A variety of other
diagnostic tests have been investigated as less invasive ways to assess sphincter of Oddi dysfunction
and determine who is likely to beneﬁt from sphincterotomy, including magnetic resonance chol-
angiopancreatography, ultrasonographic assessment of duct diameter after stimulation, and radio-
nuclide ﬂow during choledochoscintigraphy [73]. Some of these appear to be useful in experienced
hands, but data on their sensitivity and speciﬁcity is still lacking, especially in terms of long-term
clinical outcomes that are of direct beneﬁt to the patient. It should also be noted that in the medical
cohort follow-up study reported by Vitton et al, [90] 67% of Type II criteria had improvement without
sphincterotomy over one year, so an empirical trial of medical treatment (in this study, trimebutine
200 mg three times per day and/or nitrates) can reasonably be considered prior to attempting invasive
diagnostic procedures.
The Rome III diagnostic criteria for the sphincter of Oddi disorders include that ‘the pain is moderate
to severe enough to interrupt the patient’s daily activities’, which suggests that the indirect medical
and social costs borne by the patient are likely to be high. A variety of symptoms and functional status
questionnaires have been used in clinical studies, including some that measure the degree of disability
caused by abdominal pain [91]. As investigations into sphincter of Oddi dysfunction diagnosis and
treatment progress, the cost-effectiveness in terms of indirect cost–beneﬁts to patients will be
important to capture.
Functional pancreatic sphincter of Oddi disorder
The distinction between functional pancreatic sphincter of Oddi disorder and the biliary
correlate per the Rome III criteria is the presence of elevated pancreatic enzymes [73]. Accordingly,
the major clinical difference is the need to rule out the other potential causes of chronic pancre-
atitis. In their case-series of 305 patients meeting criteria for sphincter of Oddi dysfunction, only 16
patients (5.3%) were deﬁnitively the pancreatic type, and three of those were known to have stones
deep in the pancreatic duct [84]. The diagnostic evaluation needed to establish the diagnosis of
pancreatic sphincter of Oddi disorder, including MRCP and ERCP with manometry, is very expen-
sive. Furthermore, the treatment – total division of the sphincter of Oddi, is an invasive and
technically difﬁcult procedure. Therefore, there is little about this syndrome that currently lends
itself to cost-effectiveness analysis.
Functional disorders of the anus and rectum
The ﬁnal category of adult functional gastrointestinal disorders is devoted to the series of
anorectal symptoms about which the etiologies are unknown, or thought to be related to the
abnormal functioning of normally innervated and structurally intact muscle, or attributed to psy-
chological causes [92]. In keeping with the Rome III system, they are classiﬁed by symptom criteria,
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These are very common syndromes, some of which affect more than one in ten adults, but often
underappreciated by clinicians because patients are often embarrassed to discuss them.Functional fecal incontinence
This syndrome is deﬁned as recurrent uncontrolled passage of fecal material in a personwho has no
evidence of neurologic of structural etiologies [92]. In contrast to almost all of the other functional
gastrointestinal disorders, the Rome III diagnostic criteria allow some minor structural abnormalities,
such as anal sphincter defects, because they are very common and not always causally associated with
fecal incontinence [93]. However, the Rome III criteria do exclude major central nervous system dis-
eases (e.g., multiple sclerosis), systemic neuropathies (e.g., diabetic neuropathy), or systemic diseases
that include anal sphincter abnormalities as just one of their many dermatologic or mucosal injuries
(e.g., scleroderma).
Functional fecal incontinence is very common and the epidemiology has been studied in many
population-, survey-, and clinic-based studies internationally [94]. The National Health and
Nutrition Examination Survey (NHANES) is a large stratiﬁed cross-sectional survey that collects a
wide array of demographic, questionnaire, physical exam, and testing data from patients who are
targeted to help comprise a representative sample of the United States non-institutionalized
population [95]. In 2005–2006, the NHANES included a validated Fecal Incontinence Severity
Index that was administered to 2229 women and 2079 men who were aged 20 and older. The
prevalence was similar in women (8.9%) and men (7.7%), and increased linearly with age (2.6% in
20–29 years-old, and 15.3% in participants aged 70 years and older). After adjusting for age, fecal
incontinence was not associated with race/ethnicity, education, income, or marital status. Inde-
pendent risk factors in women included advanced age, loose or watery stools, more than 21 stools
per week, multiple chronic illnesses, and urinary incontinence; in men they included advanced age,
loose or watery stools, poor self-rated health, and urinary incontinence [95]. A population-based
survey of women in Minnesota found even higher prevalence (12.1% (95% CI: 11.0–13.1)) espe-
cially among those in the sixth decade (22%) [96]. This study also demonstrated that fecal incon-
tinence had substantial impact on the quality of life of those who had moderate (50% of afﬂicted)
and severe (5% of afﬂicted) symptoms.
The diagnostic evaluation of fecal incontinence is potentially complex due to the wide variety of
different causal mechanisms, but the information obtained during an ordinary history and physical
exam can substantially reduce the need for testing [93]. For example, a digital rectal exam can quickly
and objectively identify diarrhoea or constipation as causal factors [95]. There are no current cost–
beneﬁt analyses on the diagnostic testing for fecal incontinence, but this is an area where a logical
decision tree for diagnostic testing can reduce wasteful utilization.
The ﬁrst line of therapy for this syndrome is to restore normal bowel habits, especially if there is
severe constipation or diarrhoea [93]. Biofeedback is also a relatively non-invasive and inexpensive
intervention that has had very good results in some but not all studies [97].
Patients with functional fecal incontinence have substantially increased direct and indirect costs,
and societal cost (e.g., lost time from work and disability costs) can be substantial as well since these
are often younger persons [98]. In a survey of 535 patients who self-reported as having fecal incon-
tinence, direct medical costs were overall 55% higher than those of similar patients from the same
medical system who did not have fecal incontinence [99]. Only 15 of these patients had a physician’s
diagnosis of fecal incontinence recorded in their medical records within the ﬁve years prior to the
survey. In another survey of 332 patients who did have a physician diagnosis of fecal incontinence, the
mean annual direct costs for fecal incontinence related care was $2383 USD (median, $1594; inter-
quartile range, $517–$5164), and indirect cost attributable to lost productivity averaged $1549 per
patient (median, $0; interquartile range, $0–$813) [100].
A variety of symptoms measures, quality-of-life, and utility measures have been validated in
fecal incontinence, particularly in women [101,102]. These are being applied to cost-effectiveness
and cost–beneﬁt analyses for some of the newer, more invasive, and more expensive
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jection of bulking agents [105].
Functional anorectal pain
The functional anorectal pain category is divided into two symptom sub-categories: chronic
proctalgia and proctalgia fugax [93,106]. They are distinguished by the pain quality, duration, and
frequency, and it is possible for patients to have both [92]. The Rome III criteria require the
exclusion of other potential causes of rectal pain (e.g., ﬁssures, hemorrhoids, prostatitis), so
completion of a thorough examination and work up to exclude these other diseases is assumed in
this discussion. The epidemiology of the functional anorectal pain syndromes is difﬁcult to describe
due to the variety of names they have been given and different criteria used for diagnoses. In a
population-based surveys of functional gastrointestinal disorders in Mexico, proctalgia fugax was
more prevalent (6.2% (95% CI: 4.3–8.7%)) than levator ani syndrome (1.4% (95% CI: 0.6%–2.9%)) [57],
which was also true in Australia (6.6% (95% CI: 4.8–8.3%) and 1.2% (95% CI: 0.4% and 1.9%)
respectively) [9]. In a postal survey of functional gastrointestinal disorders among 5430 adults in
the United States, the prevalence of levator ani syndrome was 6.6%, and was more common among
women (7.4%) than men (5.7%) [83].
Chronic proctalgia
Levator ani syndrome and unspeciﬁed functional anorectal pain. Chronic proctalgia has been given
several names including levator ani syndrome, levator spasm, puborectalis syndrome, pyriformis
syndrome, and pelvic tension myalgia, but the Rome III system simply divides this subclass into the
levator ani syndrome and unspeciﬁed functional anorectal pain [93,106]. The pain in both is
described as a vague, dull ache or pressure sensation high in the rectum, often worse with sitting
than with standing or lying down. The distinction between them is based purely on the digital
rectal exam: in the levator ani syndrome, there is tenderness during posterior traction on the
puborectalis, and in unspeciﬁed functional anorectal pain, there is no tenderness. For the chronic
proctalgias, the pain episodes should last at least 20 min and the syndrome onset should be at least
six months prior to diagnosis, with symptoms meeting the diagnostic criteria for the prior three
months [93].
The most popular hypothesis for the aetiology of the chronic proctalgias is that they are caused
by chronic tension or spasm of the striated muscles of the pelvic ﬂoor [92,106]. This was examined
in a study comparing biofeedback relaxation techniques to electrogalvanic stimulation (EGS) and
massage treatment [107,108]. After initial screening, 157 patients with chronic proctalgia (94 le-
vator ani syndrome, 63 unspeciﬁed functional anorectal pain), each of whom had extensive
physiologic testing, patients were stratiﬁed based on the evidence of posterior rectal tenderness
on digital rectal exam, then randomized to one of the three treatments. Among those with levator
ani syndrome, 87% reported adequate relief with biofeedback, as compared to 45% for EGS, and
22% for message. Pain days per month decreased from a baseline mean of 14.7 to 3.3, 8.9, and 13.3,
respectively. Pain intensity also decreased from 6.8 on the standard 0 (none) to 10 (maximum)
scale to 1.8, 4.7, and 6.0, respectively. The patients with unspeciﬁed functional anorectal pain did
not beneﬁt from any of these treatments [107]. The physiologic testing demonstrated that those
patients who reported improvement with any of these treatments had signiﬁcant improvement in
the ability to relax pelvic ﬂoor muscles, as well as increased rectal sensitivity. The authors
concluded that the mechanism by which these three treatments reduce levator ani symptoms was
similar, but their effectiveness was different. The results of these three treatment approaches
have varied widely in other studies, but all are currently considered reasonable treatment
options [106].
Other treatments have also been tried in chronic protalgia, most of which are also based on the
sustained dysfunctional pelvic muscle contraction theory. Cyclobenzaprine, a popular muscle relaxant
for back spasms, has been tried with some success [109]. Botulinum toxin injections were tested in a
small randomized cross-over study of 12 patients, but did not have signiﬁcant beneﬁt in terms of pain
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proctalgia, but survey data suggest that the impact on patients in terms of pain symptoms and debility
can be very high [83].
Proctalgia fugax
Proctalgia fugax is described as sudden severe pain in the anal area that lasts seconds to mi-
nutes, then disappears completely [92,106]. The Rome III criteria specify that the pain is localized to
the anus or lower rectum, and that for research purposes patients should have symptoms for
more than three months, but for clinical purposes the evaluation and diagnosis can be made before
then [93].
Episodes of proctalgia fugax tend to be infrequent, making investigation into the causal mechanisms
difﬁcult. In one case-series report of proctalgia fugax symptoms among patients treated for other
gastrointestinal disorders, the symptoms occurred less than ﬁve times per year in 51% of cases, and
episodes lasted for less than one minute in 57% of cases [111]. For most patients, after a diagnostic
evaluation to rule out other causes of rectal pain, reassurance is sufﬁcient. For those with prolonged
symptoms episodes, salbutamol was demonstrated to be effective in one randomized, double-blind,
placebo-controlled, cross-over trial of inhaled salbutamol in 18 patients [112]. Cost-effectiveness an-
alyses have not been published for this syndrome.
Functional defecation disorders
The symptoms criteria for the functional defecation disorders are the same as for functional con-
stipation [Section Functional constipation] [93]. The distinction between them is that the diagnosis of a
functional defecation disorder requires that the patient hasmanometric, electromyogram, or radiologic
evidence of either inadequate contraction to generate propulsive force, or failure to relax the pelvic
ﬂoor muscles during repeated attempts to defecate. The Rome III criteria also require that there is
evidence of incomplete evacuation [93].
Dyssynergic defecation & inadequate defecatory propulsion
The number of testing options to evaluate constipation, pelvic ﬂoor neuromuscular function, and
colorectal motility have rapidly expanded in recent years [113]. If ‘alarm symptoms’ are absent and the
usual empiric and relatively inexpensive treatments for constipation have failed, then the choices of
possible diagnostic tests range widely in technical complexity, invasiveness, and cost. The cost-
effectives of various algorithms to make the diagnosis of pelvic ﬂoor dyssynergia should be made in
the context of the overall evaluation of constipation.
The success of biofeedback, and the similarities in physiology mentioned with the levator ani
syndrome, make it likely that these are different manifestations of the same physiologic problem, with
the only difference being that levator ani patients have pain characteristic of that syndrome [107,108].
Discussion
As emphasis on improving the quality of healthcarewhile reducing the cost has intensiﬁed in recent
years, interest in evidence-based medicine and publications of cost-effectiveness analyses have grown
accordingly. Some of the cost-effectiveness analyses in a few of the functional gastrointestinal disor-
ders represent the state-of-the-science in this ﬁeld and excellent examples of quality cost-effectiveness
analyses [114]. The studies that support the ‘test and treat’ approach to management of dyspepsia [27–
31], and celiac disease screening in IBS [52–54] illustrate how cost-effectiveness analyses can support
current treatment guidelines.
Cost-effectiveness analyses are often a secondary or tertiary outcome analyses in randomized
clinical trials, or retrospective surveys of administrative databases, both of which can be useful and
interesting but often limited by the quality of the data. When designing studies intended to improve
the care of patients with gastrointestinal dysfunctions, it will be very useful a priori to contemplate the
types of data that are needed for cost-effectiveness, cost–beneﬁt, or cost–utility analyses, because these
are the types of evidence that will be need to prove the beneﬁts of speciﬁc interventions in the future.
Practice points
 After excluding cardiac disease, initial empiric treatment of functional chest pain as gastro-
esophageal reﬂux is cost-effective as compared to pursuing a full diagnostic evaluation.
 The ‘test and treat’ approach to dyspepsia management is cost-neutral as compared to
empiric anti-acid therapy in most populations, and cost-effective in regions with high H.
pylori infection rates.
 H. pylori eradication therapy for those who test positive by the 13C breath test results in
improved symptoms and reduced overall costs.
 Serologic screening for celiac disease among persons diagnosed with irritable bowel syn-
drome is cost-effective, especially in populations with high celiac disease prevalence.
Research agenda
 Cost–beneﬁt analyses of diagnosis and treatment algorithms for chronic diarrhoea and
constipation could help deﬁne the most effective testing and treatment strategies.
 Validation of cost–utility measures for the common functional gastrointestinal disorders is
needed for comparison of treatment cost-effectiveness relative to other chronic diseases.
 The cost–beneﬁt of cholecystectomy for functional gallbladder disorder as compared to
conservative medical management needs examination from patient, provider, and societal
perspectives.
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